Recent 8-K filings for BRNS

• May 21, 2026, 6:03 AM ET other material materiality 0.15 positive item 5.07

  Barinthus shareholders approve Scheme of Arrangement with 99.98% support

  Court Meeting: 99.98% by value of Scheme Shares voted for the Scheme of Arrangement (24,709,337 for, 3,772 against).

• April 30, 2026, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track

  Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.

• April 22, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02

  Barinthus appoints Douglas Swirsky as CFO, effective May 1, 2026

  Swirsky appointed Chief Financial Officer and principal accounting officer, effective May 1, 2026.

• March 31, 2026, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Barinthus Bio principal accounting officer Gemma Jones to step down April 30, 2026

  Gemma Jones, serving as principal accounting officer via CFGI, notified company of resignation effective April 30, 2026.

• March 13, 2026, 7:59 PM ET M&A materiality 0.85 neutral item 2.02item 7.01item 9.01

  Barinthus Bio reports FY2025 net loss $66.5M; merger with Clywedog on track for Q2 2026

  Proposed all-stock merger with Clywedog expected to close Q2 2026; combined entity to trade as CLYD.

• February 23, 2026, 6:59 PM ET M&A materiality 0.50 neutral item 1.01item 9.01 ◈ Material Agreements

  Barinthus (BRNS) amends merger with Clywedog: exchange ratios set, timeline extended to June 30, 2026

  Scheme Exchange Ratio set between 0.1 and 0.166667; Merger Exchange Ratio set between 0.000305 and 0.000508.

• January 6, 2026, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR

  On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).

• December 10, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease

  VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.

• November 7, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Barinthus Bio Q3 net loss $14.6M; all-stock merger with Clywedog

  Net loss of $14.6M ($0.36/share) in Q3 2025 vs $21.1M loss in Q2 2025.

• September 30, 2025, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 7.01item 9.01

  Barinthus (BRNS) merges with Clywedog; Clywedog stockholders to own ~66% of combined company

  Clywedog stockholders will receive ~4.36 Topco shares per Clywedog share; Barinthus shareholders receive 1 Topco share per share.

• August 8, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Barinthus Bio amends 8-K to correct VTP-850 trial statement; reports Q2 net loss of $21.1M

  Net loss $21.1M ($0.52/share) vs $19.7M ($0.49/share) in Q1 2025.

• August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027

  Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.

• June 10, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Barinthus Biotherapeutics shareholders approve all proposals at 2025 AGM

  Resolutions to re-elect directors Pierre A. Morgon and Joseph C. Scheeren passed with ~98.9% of votes cast.

• May 7, 2025, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 5.02item 7.01item 8.01item 9.01 ◈ executive_change ×3

  Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data

  Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.

• March 20, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Barinthus Bio FY2024 net loss $61.1M; cash runway into 2027; VTP-1000 data Q3 2025

  Net loss of $61.1M ($1.55 per share) vs $73.3M in 2023; goodwill impairment of $12.2M.

• January 10, 2025, 6:59 PM ET other material materiality 0.85 negative item 2.02item 2.05item 5.02item 7.01item 9.01 ◈ executive_change ×2

  Barinthus Bio restructures: cuts 65% workforce, shifts focus to celiac VTP-1000

  Workforce reduction of ~65%; plans to close UK site, consolidate operations in Germantown, MD.

• November 25, 2024, 6:59 PM ET leadership materiality 0.45 neutral item 5.02item 8.01item 9.01 ◈ executive_change

  Barinthus Bio promotes Geoffrey Lynn to CSO; Nadège Pelletier steps down

  Nadège Pelletier to step down as Chief Scientific Officer effective Feb 2, 2025; she served since early 2023.

• November 15, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b

  IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.

• November 6, 2024, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026

  Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.

• September 5, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Barinthus Biotherapeutics promotes Graham Griffiths to COO effective Sept 1, 2024

  Graham Griffiths promoted from Chief Business Officer to COO, effective Sept 1, 2024.

• August 8, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired

  Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.

• June 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01

  Barinthus prioritizes VTP-300 (CHB) and VTP-1000 (celiac); cuts workforce 25%, extends cash runway to Q2 2026

  Pipeline focused on VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease; ongoing Phase 1 trial of VTP-850 in prostate cancer to be completed.

• June 6, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Barinthus Bio VTP-300 data: 76% eligible to stop NUC therapy; significant HBsAg reduction vs placebo

  HBV003 (Phase 2b): 76% (16/21) eligible for NUC discontinuation; 19% achieved undetectable HBsAg.

• May 15, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×8

  Barinthus shareholders approve all proposals at 2024 AGM, re-elect directors

  Three directors re-elected: William Enright, Alex Hammacher, Robin Wright with >98% of votes cast.

• May 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 7.01item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed

  Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.

• May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial

  Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

5 positive 5 negative 16 neutral

source · BRNS on sec.gov